3/1/2011 | CVLM | King Pharmaceuticals holders put $397.31 million 1.25% convertibles
|
1/31/2011 | CVLM | King tenders for all $400 million of 1.25% convertible notes due 2026
|
10/12/2010 | CV | Market Commentary: Planned Ciena deal adds 0.5 point in the gray; existing Ciena notes mixed; King Pharma up
|
10/12/2010 | IG | Fitch: Pfizer unaffected
|
10/12/2010 | BKCVHY | Moody's may lift King Pharmaceuticals
|
8/16/2010 | CV | Market Commentary: Convertibles muted; MannKind to price $100 million deal; King Pharma quiet as shares add
|
8/9/2010 | CV | Market Commentary: Convertibles quiet; Beckman Coulter recoups a little; King Pharmaceuticals down a point
|
5/14/2010 | BK | King Pharmaceuticals completes $500 million revolving credit facility
|
5/11/2010 | BKCVHY | S&P affirms King, rates loan BBB-
|
5/6/2010 | BK | King Pharmaceuticals to get $500 million revolving credit facility
|
4/28/2010 | BKCVHY | Moody's rates King Pharmaceuticals loans Ba1
|
4/7/2010 | CV | Market Commentary: Telvent rises in quiet debut; JA Solar, solar names active; Massey Energy extends losses
|
4/1/2010 | CV | Market Commentary: Corporate Office slips on debut; Micron trades up in line after earnings; Medtronic active
|
2/26/2010 | CVHY | King Pharmaceuticals files automatic shelf for stock, preferreds, debt
|
12/4/2009 | CV | Market Commentary: AMR, UAL extend gains; Take-Two holds up on hedge, stock sinks; King Pharma, Lions Gate up
|
11/5/2009 | BK | King Pharmaceuticals pays down entire $28.7 million term loan
|
8/6/2009 | BK | King Pharmaceuticals repays $102.1 million of revolver borrowings
|
7/21/2009 | SS | SEC slaps Perry Corp. with $150,000 fine for violating securities law
|
5/11/2009 | BKBWCVHY | King Pharmaceuticals repays $48 million of debt in first quarter
|
1/7/2009 | BK | Moody's ups King Pharma loans to Ba2
|
12/31/2008 | SS | King Pharmaceuticals acquires Alpharma for $37 per share
|
12/31/2008 | SS | Alpharma shareholder Gamco rescinds proposal in light of King Pharmaceuticals' offer
|
12/24/2008 | SS | Market Commentary: Johnson & Johnson tender offer for Omrix expires Friday; Emageon buyout lacks financing
|
12/22/2008 | BK | Market Commentary: LCDX, cash steady, shrugging off stock dip; Ford, GM hold firm
|
12/22/2008 | SS | King extends tender offer for Alpharma to Dec. 29
|
12/22/2008 | SS | Market Commentary: Johnson & Johnson, King Pharma buyouts considered done deals; InfoGroup founder explores sale
|
12/16/2008 | BK | King Pharmaceuticals downsizes term loan to $200 million
|
12/16/2008 | BK | Market Commentary: Precision Drilling zeroing in on carve-out details; King Pharmaceuticals trims term loan; LCDX rises
|
12/2/2008 | BK | Market Commentary: Ford, GM rev higher as plans submitted to Congress; Banks could be the ticket for King Pharmaceuticals
|
12/1/2008 | BK | Market Commentary: King Pharmaceuticals may see OID widen; GM, Ford head higher; Cash, LCDX slide
|
11/26/2008 | SS | Market Commentary: BCE deal on brink; King seeks other financing to buy Alpharma; Constellation buyout gains opposition
|
11/25/2008 | SS | Market Commentary: Rio Tinto falls after BHP backs out; Exelon forges ahead with NRG bid; PNM clears step in gas sale
|
11/24/2008 | CV | Market Commentary: Citigroup jumps on government rescue; B of A, Wachovia rise; Alpharma little changed on merger news
|
11/24/2008 | SS | King Pharmaceuticals, Alpharma agree to combine
|
11/24/2008 | SS | Market Commentary: Citi rescue sparks rally; King takes Alpharma for $37 a share; J&J to buy Omrix; LandAmerica sinks
|
11/20/2008 | BK | King Pharmaceuticals reworks deal, launches as $300 million term loan talked at Libor plus 500 bps
|
11/20/2008 | BK | Market Commentary: Autos drop as bailout hits glitch; Cash, LCDX fall; Aquilex tweaks deal; King launches with new structure
|
11/17/2008 | BK | King Pharmaceuticals delays $1 billion credit facility launch till Thursday
|
11/17/2008 | BK | Market Commentary: King resets launch; Chanticleer commitment expires; Pipeline Data fades away; Cash, LCDX fall
|
11/14/2008 | BK | King Pharmaceuticals to launch $1 billion credit facility on Tuesday
|
10/13/2008 | SS | King Pharmaceuticals' offer for Alpharma extended to Nov. 21
|
10/8/2008 | SS | Gabelli, Gamco purchase 478,500 Alpharma shares for 9.5% stake
|
10/6/2008 | SS | King Pharmaceuticals, Alpharma announce confidentiality agreement
|
10/6/2008 | SS | Market Commentary: Wachovia war hits the courts but short truce declared; International Rectifier rebuffs Vishay
|
9/29/2008 | BKCV | S&P assigns King loan BBB-, convertibles BB
|
9/29/2008 | SS | FTC wants more information about proposed merger of King Pharmaceuticals, Alpharma
|
9/29/2008 | SS | Market Commentary: Wachovia plummets on banking-asset sale; ImClone, Alpharma savor mystery suitors
|
9/26/2008 | BK | Market Commentary: Fresenius Kabi widens OID, breaks for trading; Cash sees shortage of buyers; LCDX holds steady
|
9/26/2008 | SS | Alpharma continues to reject King's offer, enters into confidentiality agreements with other parties
|
9/26/2008 | SS | Market Commentary: WaMu nosedives on U.S. seizure, industry wonders who's next; Alpharma says other offer tops King;
|
9/25/2008 | BKCV | Moody's rates King Pharma loans Ba2
|
9/24/2008 | SS | Gabelli continues to buy shares of Alpharma
|
9/19/2008 | SS | Gabelli buys 393,800 shares of Alpharma for 8.42% stake
|
9/17/2008 | BK | King Pharmaceuticals details $1 billion credit facility for Alpharma bid
|
9/17/2008 | SS | Gabelli continues to invest in Alpharma, reports 7.38% interest
|
9/12/2008 | SS | King Pharmaceuticals begins tender offer for Alpharma
|
9/12/2008 | SS | Market Commentary: Lehman, WaMu stutter along; King tenders for Alpharma; Longs holders shun CVS as Walgreen steps in
|
9/11/2008 | SS | King Pharmaceuticals to begin $37-per-share cash tender offer for Alpharma
|
9/10/2008 | SS | Gabelli ups stake in Alpharma to 5.54%
|
9/2/2008 | SS | Alpharma adopts rights plan, amends change-in-control plan
|
9/2/2008 | SS | Market Commentary: Lehman gyrates as KDB may take stake; Alpharma prescribes poison pill
|
8/26/2008 | SS | Gabelli, Gamco report 5.05% stake in Alpharma
|
8/25/2008 | BKCV | Moody's affirms King
|
8/22/2008 | CV | Market Commentary: Lehman jumps on speculation; King holds, Alpharma up on takeover bid; China Sunergy up on earnings
|
8/22/2008 | SS | King Pharmaceuticals makes public its $33-per-share offer for Alpharma
|
8/22/2008 | SS | Market Commentary: King reveals nixed bid for Alpharma; Genentech will pay to keep staff; Sovereign gyrates on GSE fears
|
6/30/2008 | BKCV | S&P cuts King outlook to negative
|
5/21/2008 | BKCV | Moody's rates King Pharma SGL-1
|
11/20/2007 | CVHY | Moody's gives King loan Ba3
|
4/25/2007 | CV | S&P raises King Pharmaceuticals outlook to stable
|
3/28/2007 | CV | Moody's cuts King Pharmaceuticals view to negative
|
11/9/2006 | BT | King Pharmaceuticals third-quarter revenues decrease, branded sales fall
|
10/18/2006 | BT | King Pharmaceuticals makes $37.75 million loan available to Ligand
|
10/13/2006 | BTCV | King Pharmaceuticals calls 2.75% convertibles
|
9/21/2006 | BKBTCVHY | Moody's revises ratings for nine U.S. pharma companies
|
9/21/2006 | BT | Depomed, King Pharmaceuticals considering agreement for Glumetza combination product
|
9/15/2006 | BT | King: Ramipril not effective diabetes drug at three-year mark
|
9/7/2006 | BT | King Pharmaceuticals to acquire Avinza from Ligand for $265 million
|
9/7/2006 | BT | Market Commentary: New River falls over 10%; Cell Genesys loses 5% after-hours; Ligand, King up; Sinovac up 7%
|
8/23/2006 | BT | Market Commentary: Cell Therapeutics' stock takes off on positive phase 1 data; Cubist's stock up again on Theravance news
|
8/23/2006 | BT | Depomed, King Pharmaceuticals to launch Glumetza as new ADA guidelines are issued
|
8/9/2006 | BT | King Pharmaceuticals says second-quarter revenue up 8% over last year
|
8/9/2006 | BT | Market Commentary: Palatin up; Genaera gouged by reverse split plans; Onyx off; RegeneRx up; KOS up
|
8/2/2006 | BT | Pain Therapeutics, King start phase 1 trial for Oradur-based pain reliever
|
7/18/2006 | BT | King Pharmaceuticals: court upholds patent claims for Altace, rules agains Lupin
|
7/6/2006 | BT | King, Wyeth amend agreement to market, sell Altace to reduce risk of heart attack and stroke
|
6/28/2006 | BT | King Pharmaceuticals, Depomed to co-promote Glumetza for type 2 diabetes
|
6/28/2006 | BT | Market Commentary: Replidyne debut shaky but closes in the green; Indevus rises in face of spot sale; Depomed loses 3%
|
6/22/2006 | BT | Palatin, King Pharmaceuticals say bremelanotide helps sexual dysfunction patients
|
6/2/2006 | BTCV | King Pharmaceuticals gets tenders for 97.61% of 2.75% convertibles
|
5/26/2006 | BTCV | King Pharmaceuticals extends tender offer for 2.75% convertibles to June 2
|
5/16/2006 | BT | Market Commentary: Neurocrine, DOV dive; Novavax, Generex dive amid noise of exits; Adventrx slips modestly on deal
|
5/5/2006 | BT | Durect begins pivotal phase 3 program for pain medicine Remoxy
|
5/4/2006 | BT | Palatin, King complete enrollment in two phase 2b trials of bremelanotide in erectile dysfunction patients
|
4/28/2006 | BTCV | King Pharmaceuticals tenders for 2.75% convertibles
|
4/6/2006 | CV | Market Commentary: Allergan new deal stumbles in the gray; Annaly offering seen as hedge play; Cell Therapeutics plans deal
|
3/30/2006 | BTCV | King Pharmaceuticals buys back $165 million of convertibles
|
3/27/2006 | CV | Market Commentary: Lucent preferreds climb on hopes of post-merger tender; Time Warner Telecom stock upgrade boost
|
3/24/2006 | BT | Moody's affirms King Pharmaceuticals
|
3/24/2006 | CV | Market Commentary: Cephalon setback positive for hedged players; Lucent strengthens on merger talks; BioMarin starts strong
|
3/24/2006 | BTCV | New Issue: King Pharmaceuticals prices $400 million of 20-year convertibles at 1.25%, up 0%
|
3/24/2006 | BT | King: FDA may require another trial for Altace to treat pediatric hypertension
|
3/23/2006 | BT | Market Commentary: BioMarin, King deals on deck; Cephalon poised to slide Friday; CombinatoRx off on PIPE deal
|
3/23/2006 | CV | Market Commentary: BioMarin new deal gets thumbs-up; YRC weaker on poor outlook; Cephalon fails to get FDA nod
|
3/22/2006 | BTCV | King Pharmaceuticals to repurchase, redeem 2.75% convertible debentures
|
3/22/2006 | BT | Market Commentary: Cephalon seesaws; Nabi zooms; Endo drops; Insmed off; Elan, Biogen drop; King launches deal
|
3/22/2006 | CV | Market Commentary: General Motors rises on union deal; Cephalon see-saws on drug prospects; Interpublic cut by S&P
|
3/22/2006 | BTCV | King Pharmaceuticals to offer $400 million of 20-year convertibles talked at 0.75%-1.25%, up 20%-25%
|
3/3/2006 | BT | Market Commentary: Angiotech to sell bonds, bank debt; Advanced Magnetics rises; Celgene on tear of new highs
|
3/2/2006 | BT | King acquires exclusive rights to EpiPen in Canada
|
2/28/2006 | BT | King Pharmaceuticals says 2005 revenue up 36% to $1.77 billion
|
2/28/2006 | BT | King, Aventis, Cobalt agree to dismiss Altace patent litigation
|
2/28/2006 | BT | Market Commentary: Generex recoils along with most flu names; King Pharma clubbed; Elan, Biogen hit by analyst poll
|
2/16/2006 | BT | King Pharmaceuticals works with Arrow on new formulations of Altace
|
2/16/2006 | BT | Pain Therapeutics, King Pharmaceuticals receive Special Protocol Assessment for Remoxy
|
2/7/2006 | BT | Palatin, King start phase 2b clinical trial evaluating PT-141 in sexual arousal disorder patients
|
1/5/2006 | BT | King Pharmaceuticals starts phase 3 trial of Vanquix for seizures
|
1/5/2006 | BT | King Pharmaceuticals begins phase 2 trial of MRE0094 for diabetic foot ulcers
|
12/23/2005 | BT | Palatin, King terminate sublicense of Palatin, Competitive Technologies patents
|
12/9/2005 | BT | King licenses muscle-relaxant Skelaxin to Mutual for more than $35 million, royalties
|
11/22/2005 | BT | Market Commentary: Pain Therapeutics falls on poor trial data; Sinovac off of profit taking; Point Therapeutics rises
|
11/11/2005 | BT | Market Commentary: OSI Pharma, Eyetech lower; Coley steady after big net loss; King Pharma, Pain extend moves
|
11/10/2005 | BT | King Pharmaceuticals, Pain Therapeutics partner to develop, market painkiller Remoxy
|
11/10/2005 | BT | Thomas Weisel maintains King at peer perform
|
11/10/2005 | BT | Market Commentary: King Pharma off, Pain increases; ViroPharma falls on generic risk; Eyetech, OSI seesaw on merger
|
9/29/2005 | BKBTCV | S&P affirms King Pharmaceuticals, off watch
|
8/9/2005 | BT | Market Commentary: Elan, Biogen Idec up on Tysabri update; Human Genome convertible rises; Celgene, King Pharma gain
|
7/15/2005 | CV | Market Commentary: Chiron drops as convertibles market trades mostly flat to lower; but CV Therapeutics, Isis gain
|
6/23/2005 | BT | Market Commentary: Forest Labs up sharply; King sees buying; Avalon sets IPO range; Salix dives; Xoma, ViaCell bounce
|
6/14/2005 | BT | Market Commentary: Mylan tops biotech activity with big stock buyback; King issues eyed; Invitrogen convertible on tap
|
4/21/2005 | BKCV | Moody's confirms King Pharmaceuticals
|
2/28/2005 | BKCV | S&P cuts King Pharma view to negative
|
2/28/2005 | CV | Market Commentary: Elan hurt, Biogen stable; Teva up, Schering slips; King trips; Yellow skids; Manpower lower; Saks off
|
12/14/2004 | BKCV | S&P: King Pharma watch to developing
|
12/1/2004 | BKCV | Moody's cuts King Pharma loan to Ba2, converts to Ba3
|
7/26/2004 | BKCV | Moody's: King Pharma uncertain
|
7/26/2004 | BKCV | S&P: King Pharma on positive watch
|
7/26/2004 | CV | Market Commentary: King Pharma soars on merger; Boise Cascade higher on split; Marshall & Ilsley deal emerges
|
7/13/2004 | BKCV | S&P lowers King Pharma
|
5/7/2004 | CV | Moody's may lower King Pharma
|
5/6/2004 | CV | S&P: King Pharma on negative watch
|
3/12/2004 | CV | Market Commentary: King Pharma converts better as stock hurt by FDA ruling; Placer Dome bid up by volatility players
|
5/21/2003 | CV | Market Commentary: Providian's new paper soars to 104.5; Elan gains on deal for King sale; new deals continue to flow
|
4/29/2003 | CV | Market Commentary: Secondary activity picks up on influx of earnings reports; flow of small new issues continues
|
4/25/2003 | CV | Market Commentary: Amazon rise burns heavy hedges; Emulex bonds hold on stock drop; distressed buyers remain active
|
4/2/2003 | CV | Market Commentary: Allied Waste deal stands pat; energy names firm on hope from Reliant's bank victory
|
3/18/2003 | CV | Market Commentary: Mandalay prices at record premium among flurry of new deals; secondary players in hiding
|
3/17/2003 | CV | Market Commentary: Markets go green on war visibility; spate of deals hold promise for busy week
|
3/11/2003 | CV | Market Commentary: Interpublic prices, Arris launches $100 million; King Pharma dives on SEC investigation
|
2/11/2003 | CV | Moody's cuts King Pharmaceuticals outlook
|
2/11/2003 | BK | Moody's cuts El Paso
|
1/30/2003 | BK | S&P raises Lennar to investment grade
|
1/30/2003 | CV | S&P raises Lennar to investment grade
|
1/30/2003 | CV | Market Commentary: Micron trading lighter as outright buyers hold on; several drug issues gain
|
1/30/2003 | HY | S&P raises Lennar to investment grade
|
6/21/2002 | CV | Market Commentary: Profits taken in defense names, buyers seen for insurance
|
5/22/2002 | CV | Market Commentary: Adelphia firms on buzz of Rigas deal; Berkshire surprises with overnighter
|
4/10/2002 | CV | Deutsche analysts say credit work provides insight for generic drug picks
|
4/10/2002 | CV | Market Commentary: Duane Reade brings new deal in new structure; Biotechs, drugs higher on short covering
|
3/14/2002 | CV | Moody's cuts Brightpoint convertible to Ca
|
3/13/2002 | CV | S&P rates new Lucent convertible at CCC+
|
3/13/2002 | HY | Moody's puts Regional Independent on upgrade review
|
2/19/2002 | CV | Market Commentary: Convertibles lower on more selling after long weekend
|
12/11/2001 | HY | Tenders
|
11/29/2001 | HY | Tenders
|
11/13/2001 | HY | Market Commentary: Chesapeake upsizes sterling issue; Allied Waste, Revlon slate deals; Enron up on Dynegy news
|
11/12/2001 | HY | Tenders
|
11/6/2001 | CV | Market Commentary: Convertible market gains with stocks on rate cut, new deals
|
11/2/2001 | CV | New Issue: King Pharmaceuticals $300 mln 20-year cvt debs yield 2.75%, up 32%
|
11/2/2001 | CV | Market Commentary: King Pharmaceuticals trades up further after pricing; small deals join calendar
|
11/1/2001 | CV | Market Commentary: Broad rise in convertibles but eagerly awaited King Pharmaceuticals delayed
|
10/31/2001 | CV | S&P rates SuperValu convertible at BBB
|
10/31/2001 | CV | Market Commentary: Convertible market bounces with stocks, new deal pricing
|
10/30/2001 | CV | Market Commentary: Convertible market drops as stocks plummet, but buyers emerge late
|
10/29/2001 | CV | Market Commentary: Convertible market marked down in quiet session as stocks plunge
|
10/26/2001 | CV | Market Commentary: Convertible market surges with $2.6 bln of new paper
|
10/25/2001 | CV | Market Commentary: Convertible market higher, new deals get tighter
|
10/24/2001 | CV | King Pharma $300 mln convertibles talked at 2.75-3.25% yield, up 28-32%
|
10/24/2001 | CV | Market Commentary: Convertible market higher as $1 bln in new deals emerge
|